PVLA HealthcareBeta data

Palvella Therapeutics, Inc.

$152.93+4.51%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 2.2B USD
Enterprise value: 2.0B USD
Full-time employees: 29

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Not enough data: growth

Would rank #671 of 1,157 fully scored healthcare companies (bottom 43%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Palvella Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Palvella Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

48/ 100

Oct 5 48 → Nov 4 48

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

Share count up 991.3% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-3.2%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-1.7%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield9.9%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

11/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-24.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.85Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-156.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -16.10Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-46.6%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio21.18×

Yahoo FinanceOutlier capped at sector 5th/95th percentile33% base weight · Z-score 11.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.10×

Yahoo FinanceReported value33% base weight · Z-score 0.57Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Palvella Therapeutics

Is Palvella Therapeutics getting weaker?: Its latest SEC filing (Aug 4, 2026) got weaker in some ways: 12-month revenue fell 93.5%; share count up 991.3%. Its overall score is unchanged at 48/100 since Oct 28, 2026.
How is Palvella Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -3.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -3.2% vs peers 1.5% (weaker than 100% of peers).
Is Palvella Therapeutics growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Palvella Therapeutics?: Less profitable than most of its peers. Profitability scores 11/100 against 1,393 healthcare peers. Return on invested capital -156.9% vs a peer median of 4.7% (weaker than 95% of peers).Return on invested capital -156.9% vs peers 4.7% (weaker than 95% of peers).
How risky is Palvella Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 21.18× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 21.18× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Sep 30, 2024 · filed Aug 4, 2026 · compared with the quarter ended Jun 30, 2024

Got weaker

12-month revenue fell 93.5%
Share count up 991.3% (existing holders diluted)

Worth watching: Palvella Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	20.9M USD	1.4M USD	−93.5%
Net income (12 months)	−23.8M USD	−61.7M USD	+159.0%
Operating margin	-123.6%	-4270.8%	−4147.2 pts
Free cash flow (12 months)	−37.9M USD	−36.5M USD	−3.7%
Cash	19.7M USD	187.8M USD	+851.8%
Shares outstanding	1.3M	14.4M	+991.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-165.0%	-167.8%	-27.7%	—	—	—
Net margin	-145.6%	-128.5%	43.7%	—	—	—
Return on assets (ROA)	-29.8%	-34.8%	247.6%	-19.8%	-70.0%	▼ 50 pts
Return on equity (ROE)	-90.1%	—	—	-27.8%	-149.1%	▼ 121 pts
Free cash flow margin	-27.4%	-235.4%	-32.4%	—	—	—
Current ratio	2.52×	2.01×	3.20×	7.33×	5.20×	▼ 29%
Interest coverage	—	—	—	-32.78×	—	—

PVLA price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Not enough data: growth

Would rank #671 of 1,157 fully scored healthcare companies (bottom 43%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Palvella Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Palvella Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Palvella Therapeutics

Is Palvella Therapeutics getting weaker?

Its latest SEC filing (Aug 4, 2026) got weaker in some ways: 12-month revenue fell 93.5%; share count up 991.3%. Its overall score is unchanged at 48/100 since Oct 28, 2026.

How is Palvella Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -3.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -3.2% vs peers 1.5% (weaker than 100% of peers).

Is Palvella Therapeutics growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Palvella Therapeutics?

Less profitable than most of its peers. Profitability scores 11/100 against 1,393 healthcare peers. Return on invested capital -156.9% vs a peer median of 4.7% (weaker than 95% of peers).Return on invested capital -156.9% vs peers 4.7% (weaker than 95% of peers).

How risky is Palvella Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 21.18× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 21.18× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

20.9M USD

1.4M USD

−93.5%

Net income (12 months)

−23.8M USD

−61.7M USD

+159.0%

Operating margin

-123.6%

-4270.8%

−4147.2 pts

Free cash flow (12 months)

−37.9M USD

−36.5M USD

−3.7%

Cash

19.7M USD

187.8M USD

+851.8%

Shares outstanding

1.3M

14.4M

+991.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-165.0%

-167.8%

-27.7%

—

Net margin

-145.6%

-128.5%

43.7%

—

Return on assets (ROA)

-29.8%

-34.8%

247.6%

-19.8%

-70.0%

▼ 50 pts

Return on equity (ROE)

-90.1%

—

-27.8%

-149.1%

▼ 121 pts

Free cash flow margin

-27.4%

-235.4%

-32.4%

—

Current ratio

2.52×

2.01×

3.20×

7.33×

5.20×

▼ 29%

Interest coverage

—

-32.78×

—